Cross-linked Corneal Grafts for Rejection Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for corneal transplantation face challenges such as immune response rejection, vascular and fibrous tissue growth, and limited success in preserving corneal clarity, especially in repeated transplantations and cases with complex conditions like corneal ectasia and infectious diseases.
Innovation Solution
A method involving cross-linking of corneal implants using a photosensitizer like riboflavin and ultraviolet light to prevent immune response and rejection, combined with techniques like femtosecond laser processing and excimer laser modification for refractive correction, ensuring the implant is securely positioned within the cornea to maintain clarity and prevent cellular invasion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional corneal transplantation methods are used, then the procedure can be performed, but immune response rejection and graft failure occur
Solution Approach 1:
The patent applies preliminary action by cross-linking the donor cornea tissue before transplantation using riboflavin and UV irradiation. This pre-treatment modifies the donor tissue to reduce immunogenicity before it is implanted, preventing immune rejection before the problem occurs. The cross-linking process is performed on the donor cornea in advance, altering its properties to be less recognizable as foreign tissue by the recipient's immune system.
Solution Approach 2:
The patent changes the physical-chemical parameters of the donor cornea tissue through cross-linking. The riboflavin-UV treatment creates new chemical bonds and alters the molecular structure of the donor tissue, changing its immunogenic properties. This parameter change reduces the tissue's antigenicity, making it less likely to trigger an immune response while maintaining structural integrity.
2Adaptability or versatility
If repeated corneal transplantations are performed, then more severe conditions can be treated, but success rate decreases and complications increase
Solution Approach 1:
The cross-linking treatment is applied in advance to donor corneas intended for repeated transplantations or for treating complex conditions like corneal ectasia. This pre-modification ensures the tissue is optimized for transplantation before being used in challenging cases, improving the likelihood of success despite the complexity of the indication or the fact that it is a repeated procedure.
Solution Approach 2:
The patent creates a composite structure by combining riboflavin molecules with corneal tissue through cross-linking. This composite material has enhanced properties compared to native corneal tissue, including reduced immunogenicity and improved structural stability, making it suitable for repeated transplantations and complex cases where standard tissue would fail.
3Manufacturing precision
If laser surgical techniques are used for refractive correction, then vision can be improved, but post-operative pain and dry eye occur
Solution Approach 1:
The patent uses riboflavin as an intermediary substance that enables refractive correction through a different mechanism than traditional laser ablation. Instead of directly removing corneal tissue with laser energy, the riboflavin-UV cross-linking process modifies the corneal stroma to achieve refractive changes, thereby avoiding the thermal damage and pain associated with laser surgery while still achieving vision correction.
Solution Approach 2:
The patent replaces the mechanical/thermal laser ablation system with a photochemical cross-linking system. Instead of using high-energy laser beams to vaporize or melt corneal tissue, the invention uses riboflavin activated by UV light to create cross-links in the corneal collagen, achieving refractive correction through chemical modification rather than mechanical removal, thus avoiding thermal damage and associated side effects.
4Device complexity
If corneal transplantation is performed without cross-linking, then the procedure is simpler, but vascular and fibrous tissue growth occurs
Solution Approach 1:
The cross-linking treatment is performed in advance on the donor cornea before transplantation, preventing vascular and fibrous tissue growth before these complications can develop. This preliminary modification of the donor tissue creates a more stable graft that is less prone to pathological changes, eliminating the need for complex post-operative interventions while maintaining procedural simplicity.
Solution Approach 2:
The patent converts the potential harm of tissue rejection and pathological growth into a benefit by using the same UV irradiation process to create beneficial cross-links in the donor cornea. The UV light that could potentially damage tissue is instead used to create a stable, cross-linked structure that prevents pathological changes, turning a potential harmful factor into a protective mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cross-linking method significantly reduces the likelihood of graft rejection and vascularization, enhances corneal clarity, and allows for precise refractive correction, improving the success rate of corneal transplantation and reducing complications like dry eye and corneal haze.
Implementation Method 1
cross-linking of corneal implants using a photosensitizer like riboflavin and ultraviolet light
Implementation Method 2
femtosecond laser processing
Implementation Method 3
excimer laser modification for refractive correction
Data Source
AI summary
A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) cutting a circular implant from a donor cornea; (ii) cutting the circular implant into a plurality of constituent pieces; (iii) forming a small incision in a recipient cornea of an eye of a patient; (iv) forming a pocket in the recipient cornea of the eye of the patient, the pocket being accessible through the small incision in the recipient cornea, and the pocket being bounded entirely by stromal tissue of the cornea; and (v) inserting each of the plurality of constituent pieces of the implant into the pocket of the recipient cornea via the small incision, wherein the implant is cross-linked so as to prevent an immune response to the implant and/or rejection of the implant by the patient.